Immune-mediated type IV adverse drug reactions are idiosyncratic in nature, generally not related to the primary or secondary pharmacology of the drug. Due to their complex nature and rarity, these iatrogenic reactions are seldom predicted or encountered during preclinical/early clinical development stages, and often precipitate upon exposure to wider populations (i.e. phase III onwards).
Author: Thomson P, Hammond S, Naisbitt DJ. . Clin Exp Allergy. 2022 Dec; 52(12):1379-1390
